Exploring how drugs and the bone marrow environment affect acute myeloid leukemia.
Official title: Investigating the Microenvironmental Dysregulation and Polypharmacy Impact during Acute Myeloid Leukemia in an in vitro model of the human bone marrow and in vivo models.
Funded at University of Rochester · NIH-10987768 · Data updated 2026-11-12
This study is looking at how different medications and the environment around leukemia cells affect the success of chemotherapy for people with acute myeloid leukemia (AML), with the hope of finding better ways to help patients respond to treatment and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $39,957 |
| NIH project number | 1F99CA294129-01 |
| Project ID | NIH-10987768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with acute myeloid leukemia.
✕Less likely to help
Patients with other types of leukemia or those who are not currently undergoing treatment for AML may not benefit from this research.
What this research studies
This research investigates the effects of multiple medications and the bone marrow environment on acute myeloid leukemia (AML). Using advanced 3D modeling techniques, the study aims to understand how these factors influence the effectiveness of standard chemotherapy treatments. By examining both in vitro (lab-based) and in vivo (live model) systems, the research seeks to uncover the interactions between AML cells and their surrounding environment, which may lead to better treatment strategies. Patients may benefit from insights that could improve their response to chemotherapy and overall survival rates.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for patients with acute myeloid leukemia, potentially increasing survival rates.
How similar studies have gone: Previous studies have shown promising results in understanding the role of the bone marrow microenvironment in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Sharipol, Azmeer — University of Rochester
- Study coordinator: Sharipol, Azmeer
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.